IGF-2R has been found to be mutated in 60% of lung squamous cell carcinomas, while levels of IGF-2R appears to be much higher in the malignant stages of endometrial carcinomas (Kong et al., 2000; Pavelić et al., 2007). Here, IGF2R is linked to endometrial carcinoma.